Brokers Offer Predictions for OVID FY2026 Earnings

Ovid Therapeutics Inc. (NASDAQ:OVID) – HC Wainwright issued their FY2026 earnings estimates for Ovid Therapeutics in a note issued to investors on Monday, March 24th. HC Wainwright analyst R. Selvaraju anticipates that the company will post earnings of ($0.60) per share for the year. HC Wainwright has a “Buy” rating and a $3.00 price target on the stock. The consensus estimate for Ovid Therapeutics’ current full-year earnings is ($0.40) per share.

Ovid Therapeutics (NASDAQ:OVID) last released its quarterly earnings data on Tuesday, March 11th. The company reported ($0.13) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.03. Ovid Therapeutics had a negative return on equity of 39.24% and a negative net margin of 5,142.56%. The company had revenue of $0.08 million for the quarter, compared to the consensus estimate of $0.19 million.

A number of other brokerages have also recently issued reports on OVID. Oppenheimer raised Ovid Therapeutics from a “market perform” rating to an “outperform” rating and set a $4.00 price objective for the company in a report on Wednesday, January 29th. Wedbush restated an “outperform” rating and issued a $3.00 price target (down from $4.00) on shares of Ovid Therapeutics in a research report on Wednesday, March 12th. Finally, BTIG Research dropped their price objective on shares of Ovid Therapeutics from $5.00 to $4.00 and set a “buy” rating for the company in a report on Monday. One analyst has rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Ovid Therapeutics presently has an average rating of “Buy” and an average target price of $3.03.

Ovid Therapeutics Price Performance

Shares of OVID stock opened at $0.44 on Tuesday. The stock’s fifty day simple moving average is $0.60 and its 200 day simple moving average is $0.92. Ovid Therapeutics has a one year low of $0.42 and a one year high of $3.45. The firm has a market cap of $31.58 million, a price-to-earnings ratio of -0.95 and a beta of 0.29. The company has a debt-to-equity ratio of 0.18, a current ratio of 5.66 and a quick ratio of 5.66.

Hedge Funds Weigh In On Ovid Therapeutics

Institutional investors have recently modified their holdings of the stock. SG Americas Securities LLC increased its holdings in shares of Ovid Therapeutics by 83.9% in the fourth quarter. SG Americas Securities LLC now owns 37,636 shares of the company’s stock valued at $35,000 after purchasing an additional 17,172 shares in the last quarter. XTX Topco Ltd increased its stake in shares of Ovid Therapeutics by 46.2% in the 3rd quarter. XTX Topco Ltd now owns 38,230 shares of the company’s stock valued at $45,000 after buying an additional 12,076 shares during the period. Bank of America Corp DE increased its stake in shares of Ovid Therapeutics by 49.7% in the 4th quarter. Bank of America Corp DE now owns 56,733 shares of the company’s stock valued at $53,000 after buying an additional 18,841 shares during the period. FMR LLC raised its position in shares of Ovid Therapeutics by 1,907.4% during the third quarter. FMR LLC now owns 50,225 shares of the company’s stock worth $59,000 after acquiring an additional 47,723 shares during the last quarter. Finally, Velan Capital Investment Management LP acquired a new position in shares of Ovid Therapeutics during the fourth quarter valued at $65,000. 72.24% of the stock is owned by institutional investors.

Ovid Therapeutics Company Profile

Ovid Therapeutics Inc, a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies.